Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trotabresib - Celgene Corporation

Drug Profile

Trotabresib - Celgene Corporation

Alternative Names: BET inhibitor - Celgene Corporation; BMS-986378; CC 90010; QC5487; TROTA - Celgene Corporation

Latest Information Update: 26 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Quanticel Pharmaceuticals
  • Developer Bristol-Myers Squibb; Celgene Corporation
  • Class Antineoplastics; Isoquinolines; Ketones; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Astrocytoma; Glioblastoma
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 18 Nov 2023 Northwestern University in collaboration with National Cancer Institute plans a phase I trial in HER2-positive breast cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (PO) in December 2023 (NCT06137651)
  • 06 Feb 2023 Phase-II clinical trials in Solid tumours in USA (PO), prior to February 2023 (Bristol Myers Squibb pipeline, February 2023)
  • 13 Jan 2023 Trotabresib is still in phase I trials for Solid tumours (Inoperable/Unresectable, Late-stage disease) in Spain, Japan, Italy and France (PO) (NCT03220347)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top